Australian cyclosporin therapeutic monitoring method survey: 1993.
A detailed questionnaire was distributed to the 30 Australian laboratories known to provide cyclosporin-A (CsA) therapeutic drug monitoring (TDM) services with a view to evaluating the range of approaches to such monitoring. Replies were received from all 30 laboratories. The data suggested there was a wide discordance in approaches to CsA TDM due to the fact that laboratories appeared to have adopted individual approaches to this service, both in method selection(s) and proposed therapeutic range(s). In many cases, patients served were shown to travel to more distant centers for their graft, returning to their home city/town for longer term management. Hence, services of several laboratories were involved during their clinical care. A strong mandate was received from respondents for development of national guidelines for the monitoring of CsA and other immunosuppressant drugs in order to avoid such discrepancies in the future. The approaches to external analytical quality assurance (QA) and, to a lesser extent, internal quality control (QC) were generally inadequate.
Morris
R G
RG
Department of Clinical Pharmacology, Queen Elizabeth Hospital, Woodville South, South Australia.
D001315:Australia; D016572:Cyclosporine / Q000493:pharmacokinetics* / Q000592:standards / Q000627:therapeutic use; D016903:Drug Monitoring / Q000379:methods* / Q000592:standards; D017408:Guidelines as Topic / Q000592:standards; D006801:Humans; D007166:Immunosuppressive Agents / Q000592:standards; D007753:Laboratories / Q000592:standards; D011785:Quality Assurance, Health Care; D011795:Surveys and Questionnaires; D013997:Time Factors
D007166:Immunosuppressive Agents; D016572:Cyclosporine